新疆百花村医药集团股份有限公司 独立董事 2025 年度述职报告 新疆百花村医药集团股份有限公司 本人李文宝，男，1961 年出生，美国国籍，杜邦公司中央研发部药物代谢 与毒理研究博士后，美国杨伯瀚大学生物分析化学专业博士。在美国先后在杜邦 公司、科文斯公司、瑞格公司和基因实验室公司工作过，参与并领导从药物发现、 化合物优化、临床前期动物药理和毒理实验到临床试验与申报美国食品医药管理 局（FDA）的工作。曾任康肽德生物技术（上海）有限公司总经理、瀚盟生物技 术（天津）有限公司总经理、昆明科灵生物科技有限公司总经理、新疆百花村医 药集团股份有限公司副总经理、科望（苏州）生物医药科技有限公司战略发展副 总裁，苏州公司总经理、苏州复恩特药业有限公司首席执行官，现任泰平臻宝（苏 州）生物科技有限公司首席执行官。曾获得美国杨伯瀚大学优秀研究生奖、杰出 研究员奖，苏州工业园区创新领军人才奖、2022 年度姑苏创新创业领军人才计 划－重大创新团队奖等奖项。约有 25 篇文章发表在国际或国内科技杂志上，约 有 50 次报告参加国际会议和专业论坛。作为章节应邀作者，有《现代毒理学及 其应用》（上海科技出版社 2000 年），和 ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2026-008 2026 年度预计新增合同总额不超过 500 万元。 （二）日常关联交易履行的审议程序 新疆百花村医药集团股份有限公司关于全资子公司 华威医药及其子公司与康缘华威及其子公司 2025 年度日常 关联交易完成情况及预计 2026 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东会审议：否。 日常关联交易对上市公司的影响：与关联方进行的日常交易属于正常的 业务活动，在较大程度上支持了公司的生产经营和持续发展，有利于保证公司的 正常生产运营，不存在损害公司和股东利益的情形。 根据生产经营需要，新疆百花村医药集团股份有限公司（以下简称"公司"） 全资子公司南京华威医药科技集团有限公司及其子公司（以下简称"华威医药"） 拟与康缘华威医药有限公司及其子公司（以下简称"康缘华威"）发生如下关联 交易，具体如下： 一、日常关联交易基本情况 （一）日常关联交易概述 华威医药与康缘华威 ...

Investment Rating - The report maintains a "Buy" rating for the medical services industry [6] Core Views - The medical and biological sector experienced a decline of 2.77% this week, ranking 8th among the 31 primary industries in the Shenwan index. The Shanghai and Shenzhen 300 index fell by 2.19%, indicating that the medical sector underperformed by 0.59 percentage points [1] - The report highlights a new policy from the Ministry of Commerce aimed at promoting international medical tourism, which is expected to enhance the appeal of private hospitals by allowing them to tap into high-value services such as high-end physical examinations and cosmetic surgery [4] - The medical services sector's current Price-to-Earnings (PE) ratio is 30.77X, with a Price-to-Book (PB) ratio of 3.12X, reflecting a slight decrease from the previous week [3] Summary by Sections Industry Performance - The medical services sector index closed at 6472.58 points, down 4.32% for the week, while the overall medical and biological sector index fell by 2.77% [1][22] - Notable performers in the medical services sector included WuXi AppTec (0.0%) and Aier Eye Hospital (-1.8%), while companies like Sanbo Brain Science and Proprius saw significant declines of -20.7% and -16.8%, respectively [2][22] Valuation Metrics - The medical services sector's PE ratio (ttm) is 30.77X, with a one-year maximum of 41.13X and a minimum of 28.46X. The current PB ratio is 3.12X, with a one-year maximum of 4.00X and a minimum of 2.48X [3] Investment Suggestions - The report suggests focusing on high-growth areas such as ADC CDMO and the peptide CDMO in the weight loss drug supply chain, with companies like WuXi AppTec and Aier Eye Hospital recommended for their growth potential [5] - It also highlights the potential recovery in profitability for third-party medical testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry [5]

Recent Events - The control change plan has been terminated as of January 7, 2026, due to the failure of the controlling shareholder and the counterparty to reach an agreement, leading to stock resumption and subsequent price fluctuations. This matter is not expected to have a significant adverse impact on the company's operations, which remain normal [1]. Performance Overview - For the period from January to September 2025, the company achieved a revenue of 299 million yuan, representing a year-on-year growth of 2.74%. The net profit attributable to shareholders was 32.67 million yuan, reflecting a year-on-year increase of 36.41%. The company emphasized its core business in small molecule generic drugs, with project applications and approvals ranking among the industry leaders [2]. Stock Performance - As of February 13, 2026, the stock price of the company was 9.32 yuan per share, with a total market capitalization of 3.584 billion yuan. The stock has seen a cumulative decline of 23.86% this year, although it has increased by 1.53% in the last five trading days. On that day, there was a net inflow of 6.07 million yuan in principal funds, with a turnover rate of 0.98%. The company has appeared on the stock leaderboard four times this year, with the most recent occurrence on January 13 [3]. Company Status - In April 2025, the indirect controlling shareholder, Hualing Industrial Trade, was changed to a state-owned enterprise in Xinjiang, with Xinjiang Commercial and Material Asset Management Co., Ltd. holding 51% of the shares, ultimately supervised by the Xinjiang State-owned Assets Supervision and Administration Commission. This change may affect the company's long-term strategy. Currently, there are no other significant announcements from the company, but investors are advised to pay attention to regular financial reports and any official disclosures regarding control dynamics [4].

Core Viewpoint - Baihua Pharmaceutical (600721) is actively enhancing its competitive advantage in the pharmaceutical CRO and related fields, with a focus on optimizing business layout and accelerating customer expansion for high-quality development by 2026 [1] Group 1 - The company is currently conducting its annual audit work for 2025 [1] - Baihua Pharmaceutical plans to strengthen its competitive edge in the pharmaceutical CRO sector and related areas [1] - The company emphasizes the importance of technological innovation and business optimization in its future strategy [1] Group 2 - Baihua Pharmaceutical will continue to promote high-quality development and customer expansion efforts [1] - Investors are encouraged to follow the company's periodic reports for more detailed information [1] - The designated media for the company's information disclosure includes the Shanghai Stock Exchange website and specific financial newspapers [1]

证券日报网讯2月13日，百花医药（600721）在互动平台回答投资者提问时表示，关于公司2026年的经 营方向，还请关注公司拟定于2026年3月28日，即将披露的公司2025年年度报告。 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Nanjing Ximosebo Testing Technology Co., Ltd., has received the High-tech Enterprise Certificate, which will provide significant tax benefits for the next three years [1] Group 1: Company Announcement - Nanjing Ximosebo has been recognized as a high-tech enterprise for the third time, with the certificate issued on December 19, 2025, and valid for three years [1] - The company will benefit from a reduced corporate income tax rate of 15% from January 1, 2025, through 2027, in accordance with relevant tax policies for high-tech enterprises [1]

Core Viewpoint - Baihua Pharmaceutical's subsidiary, Nanjing Ximosi Bo Testing Technology Co., Ltd., has been recognized as a high-tech enterprise for the third time by the Jiangsu Provincial Department of Science and Technology, Jiangsu Provincial Department of Finance, and the State Taxation Administration of Jiangsu Province [2] Group 1 - The recognition as a high-tech enterprise indicates the company's commitment to innovation and technology development [2] - This certification may enhance the company's reputation and potentially lead to increased funding opportunities and tax benefits [2] - The repeated recognition reflects the company's sustained performance and capabilities in the high-tech sector [2]

特此公告。 新疆百花村医药集团股份有限公司董事会 新疆百花村医药集团股份有限公司 2026 年 2 月 5 日 证券代码：600721 证券简称：百花医药 编号：2026-003 新疆百花村医药集团股份有限公司关于全资孙公司 获得高新技术企业证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026 年 2 月 3 日，新疆百花村医药集团股份有限公司全资孙公司南京西默 思博检测技术有限公司（以下简称"西默思博"）收到江苏省科学技术厅、江苏 省财政厅、国家税务总局江苏省税务局联合下发的《高新技术企业证书》（证书 编号：GR2025032009000），发证日期：2025 年 12 月 19 日，有效期三年。西 默思博本次系第三次被认定为高新技术企业，根据《中华人民共和国企业所得税 法》及国家对高新技术企业的相关税收优惠政策规定，自 2025 年 1 月 1 日起连 续三年（2025 年-2027 年）享受 15%的企业所得税优惠税率。 ...

Core Viewpoint - Baohua Pharmaceutical (600721.SH) announced that its wholly-owned subsidiary, Nanjing Simasibo Testing Technology Co., Ltd. (referred to as "Simasibo"), received the "High-tech Enterprise Certificate" from the Jiangsu Provincial Department of Science and Technology, Jiangsu Provincial Department of Finance, and the State Taxation Administration of Jiangsu Province, valid for three years [1] Group 1 - Simasibo has been recognized as a high-tech enterprise for the third time [1] - The certificate was issued on December 19, 2025, with a validity period until December 19, 2028 [1]